Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression
Liza Cholin(The Ohio State University Wexner Medical Center), Georges Nakhoul(Cleveland Clinic), Jesse D. Schold(Colorado School of Public Health), Ali Mehdi(Cleveland Clinic), Rémy Daou(Saint Joseph University), Jonathan J. Taliercio(Cleveland Clinic), George Thomas(Cleveland Clinic), Tarek Ashour(Cleveland Clinic), Nazih L. Nakhoul(Tulane University), Joseph V. Nally(Cleveland Clinic), Susana Arrigain(Cleveland Clinic)
Cited by 23
Related Papers
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
|The Lancet Diabetes & Endocrinology|2019|330
Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data
|Journal of the American Society of Nephrology|2019|209
Masked Hypertension and Elevated Nighttime Blood Pressure in CKD
|Clinical Journal of the American Society of Nephrology|2016|197